Conivaptan has not been approved by the FDA for the treatment of decompensated congestive heart failure. However, in theory, vasopressin receptor antagonism would be particularly useful in this setting, and an initial study shows that it has some promise.<ref>{{cite journal |vauthors=Udelson JE, Smith WB, Hendrix GH |title=Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure |journal=Circulation |volume=104 |issue=20 |pages=2417â€“23 |date=November 2001 |pmid=11705818 |doi= 10.1161/hc4501.099313|url=http://circ.ahajournals.org/cgi/pmidlookup?view=long&pmid=11705818|display-authors=etal}}</ref>
